Dr. Donna Kay Maneice, MD

Dr. Maneice practices at Clinic For Rheumatic Diseases in Northport, Alabama.

Dr. Maneice's NPI, 1932288339, was assigned on November 4, 2006. Dr. Maneice graduated from Heersink School of Medicine - Birmingham in 1989. Dr. Maneice's Alabama license number on file is 15326.

Dr. Maneice's primary practice is Clinic for Rheumatic Diseases, at 4280 Watermelon Rd Suite 112 Suite 112, Northport, AL 35473-5250. The practice phone is (205) 750-0030.

Dr. Maneice's primary practice is Clinic For Rheumatic Diseases in Northport, Alabama. The medical group on file is Clinic for Rheumatic Diseases. Dmand AI also links Dr. Maneice to 1 more group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Maneice practices, 2 sites in all. Vendor and product names are available with a free account.

Rheumatology is Dr. Maneice's primary specialty in the NPI Registry, under taxonomy code 207RR0500X. Dr. Maneice is board certified in rheumatology by the American Board of Internal Medicine. Dmand AI has Dr. Maneice's licenses on file in 2 states: Alabama and Georgia.

CMS data shows 12,695 Medicare services from Dr. Maneice across 22 procedure codes in 2024, for 199 Medicare patients. Medicare paid $204,101 for them. Every service was in an office.

CMS counts 199 Medicare patients who saw Dr. Maneice in 2024. The largest group is 65 to 74, with 90 patients. 75% of them have arthritis, and 75% have high blood pressure. 15% are also on Medicaid. Their average risk score is 1.42, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Maneice's median patient age at 59, with 79% women.

In 2024, Dr. Maneice wrote 104 Medicare Part D claims for 48 patients. 93% of them were for generic drugs. CMS names the drug for 32 of them, across 1 drug with 11 or more claims each, at $2,348 in total drug cost. In 2018, CMS named 384 claims across 7 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 94 out of 100 for Dr. Maneice for performance year 2024, reported as part of a group. Dr. Maneice accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links Dr. Maneice to 1 clinical trial. Conditions studied include Giant Cell Arteritis and Vasculitis, Central Nervous System. Open Payments lists research payments to Dr. Maneice that name 1 trial.

CMS Open Payments shows 1,443 general payments to Dr. Maneice from 39 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 98% of the total. Abbvie Inc. paid the most, $4,189. It also lists 15 research payments totaling $1,264 in 2018, naming 1 clinical trial.

Dr. Maneice graduated from Heersink School of Medicine - Birmingham in 1989.

Dr. Maneice is in network with 8 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 8. Check the plan with the practice before a visit.